BR100 Increased By (0.1%)
BR30 Decreased By (-0.28%)
KSE100 Decreased By (-0.14%)
KSE30 Decreased By (-0.3%)
BECO 5.88 Decreased By ▼ -0.15 (-2.49%)
BML 57.95 Increased By ▲ 5.20 (9.86%)
BOP 33.93 Decreased By ▼ -0.32 (-0.93%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.80 Decreased By ▼ -0.54 (-4.38%)
FCCL 53.67 Decreased By ▼ -0.22 (-0.41%)
FCSC 5.35 Increased By ▲ 0.13 (2.49%)
FFL 17.88 Decreased By ▼ -0.15 (-0.83%)
FNEL 1.30 No Change ▼ 0.00 (0%)
HUMNL 11.15 Increased By ▲ 0.15 (1.36%)
KEL 8.04 Decreased By ▼ -0.07 (-0.86%)
KOSM 5.47 Increased By ▲ 0.09 (1.67%)
MLCF 88.11 Increased By ▲ 0.06 (0.07%)
NBP 183.40 Decreased By ▼ -3.08 (-1.65%)
PACE 11.46 Increased By ▲ 0.74 (6.9%)
PAEL 40.36 Increased By ▲ 0.42 (1.05%)
PIAHCLA 26.17 No Change ▼ 0.00 (0%)
PIBTL 17.30 Decreased By ▼ -0.02 (-0.12%)
PPL 231.15 Decreased By ▼ -1.63 (-0.7%)
PRL 34.60 Decreased By ▼ -0.35 (-1%)
PTC 67.49 Decreased By ▼ -0.07 (-0.1%)
SEARL 91.29 Increased By ▲ 0.36 (0.4%)
SSGC 26.98 Decreased By ▼ -0.19 (-0.7%)
TELE 8.58 Increased By ▲ 0.01 (0.12%)
THCCL 64.91 Increased By ▲ 4.78 (7.95%)
TPLP 9.35 Increased By ▲ 0.59 (6.74%)
TREET 24.62 Increased By ▲ 0.08 (0.33%)
TRG 71.86 Increased By ▲ 0.11 (0.15%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
Pakistan

Govt approves China's CanSinoBio COVID-19 vaccine for emergency use

  • According to an official of Drug Regulatory Authority of Pakistan (DRAP), the registration board of the authority had allowed the vaccine, approving the request of AJM Pharma (Pvt) Limited for its emergency use.
Published February 12, 2021 Updated February 12, 2021 11:50pm
By

ISLAMABAD: The government on Friday approved the emergency use of another Chinese COVID-19 vaccine from CanSino Biologics in Pakistan.

According to an official of Drug Regulatory Authority of Pakistan (DRAP), the registration board of the authority had allowed the vaccine, approving the request of AJM Pharma (Pvt) Limited for its emergency use.

Special Assistant to the Prime Minister on National Health Services Dr Faisal Sultan, in a tweet, said according to the vaccine's phase-three trials data, it had turned out to be 74.8% effective against the virus, while it also showed 100% effectiveness in preventing severe disease.

Further citing the Independent Data Monitoring Committee's report, he said in multiple countries, the vaccine was 65.7% and 90.98% effective in preventing symptomatic cases and severe diseases, respectively.

Prof Hasan Abbas Zaheer, National Coordinator of CanSinoBIO vaccine Phase III Clinical Trial in Pakistan, said DRAP approved AJM Pharma's application for emergency use Approval of CanSinoBIO vaccine in Pakistan. The application was submitted with the DRAP last month for approval on receiving results of trial.

Comments

Comments are closed for this article.